Germany's federal healthcare reimbursement program approved Delcath Systems' Chemosat with a Value 4 status, which allows treatment centers to negotiate coverage with insurers, though it falls short of a mandated reimbursement. Chemosat is a liver cancer drug delivery system for chemotherapy that got its CE mark last year and is awaiting FDA approval. The reimbursement pathway gives Delcath a significant foothold in the German market, which the company says is its most robust. Release